lukassek-shutterstock-com-bayer-
Lukassek / Shutterstock.com
19 August 2016Americas

Bayer and CRISPR close joint venture transaction

Bayer has launched a partnership with CRISPR Therapeutics.

The companies agreed to form Casebia Therapeutics in December 2015. It officially started operations today, August 19, at its base in Cambridge, Massachusetts.

The aim of the venture is to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart diseases.

Axel Bouchon, CEO of Casebia, said: “We are excited to engage the broader life science community in Boston now through Casebia.”

He added: “As we establish and grow Casebia’s therapeutic programmes, this new location will provide us with state-of-the-art infrastructure, access to the vibrant biotech environment of the Kendall Square area, and facilitate close collaboration with CRISPR Therapeutics.”


More on this story

Generics
4 November 2021   Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.
Big Pharma
23 February 2021   Bayer Healthcare is suing medical devices manufacturer Ecomed Solutions over allegedly patent-infringing syringes.
Americas
22 October 2019   A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.

More on this story

Generics
4 November 2021   Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.
Big Pharma
23 February 2021   Bayer Healthcare is suing medical devices manufacturer Ecomed Solutions over allegedly patent-infringing syringes.
Americas
22 October 2019   A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.